“This trial emphasizes the importance of germline and somatic testing in patients with metastatic prostate cancer at the time of diagnosis; homologous recombination repair mutations have been ...

The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State ...

“The findings from Destiny-Breast09 represent a new first line standard treatment option for HER-2 positive metastatic breast cancer. The duration of therapy can now be measured in years and gives us ...

Do you know someone who would make a good ASCO President, Board member, or Nominating Committee member? In advance of the upcoming election, the ASCO Nominating Committee is seeking recommendations ...

An internationally recognized oncology leader and health care executive, Dr. Knudsen is the CEO of the Parker Institute for Cancer Immunotherapy. Dr. Knudsen was previously CEO of the American Cancer ...

Who does this study affect? People with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who develop a mutation in the estrogen receptor ...

Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...

Who does this study affect? People with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer What did this study find? The phase 3 DESTINY-Breast09 ...

Who does this study affect? People with high-risk stage II or stage III colon cancer that has been treated with surgery and chemotherapy When colon cancer has not spread to distant parts of the body, ...

Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas.

Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...